Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Winner

Arena Pharmaceuticals ( ARNA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.6%. By the end of trading, Arena Pharmaceuticals rose 35 cents (3%) to $11.81 on average volume. Throughout the day, 35 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 23.8 million shares. The stock ranged in a price between $11.46-$12.07 after having opened the day at $11.68 as compared to the previous trading day's close of $11.46. Other companies within the Drugs industry that increased today were: K-V Pharmaceutical Company ( KV.A), up 13.3%, Synageva BioPharma ( GEVA), up 10.1%, K-V Pharmaceutical Company ( KV.B), up 8.7%, and Chembio Diagnostics ( CEMI), up 7.1%.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $2.19 billion and is part of the health care sector. Shares are up 494.4% year to date as of the close of trading on Monday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and six rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.

On the negative front, Rexahn Pharmaceuticals ( RNN), down 31%, Questcor Pharmaceuticals ( QCOR), down 21.8%, Chelsea Therapeutics International ( CHTP), down 10.5%, and Somaxon Pharmaceuticals ( SOMX), down 10.3%, were all losers within the drugs industry with Celgene Corporation ( CELG) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs